Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
GreensKeeper Value Fund Michael P. McCloskey | “Our top performer in the second quarter was ICON plc (ICLR), which gained 57%. The surge followed the release of ICLR's delayed year-end and first-quarter results, which provided clarity on the accounting issues that had previously weighed heavily on the stock. ICLR had been the Value Fund's largest detractor in the first quarter, after announcing in February that it would delay its year-end results and restate its 2023 and 2024 financial statements due to revenue overstatements. The stock plummeted as investors rushed to sell amid the uncertainty. We spent the next 24 hours reviewing the company's disclosures and examining the allegations in a whistleblower lawsuit. We concluded that ICLR's ability to generate $1 billion of free cash flow was unlikely to be materially affected and that these issues would not affect its customer relationships. With the stock trading at a free cash flow yield of approximately 15%—despite remaining, in our view, a high-quality business with attractive growth prospects—we decided to materially increase our position. The delayed results released in Q2 validated our assessment. The restatement reduced reported revenue by less than 2% and had no material effect on the company's cash generation. Forward-looking indicators also look promising heading into 2027: direct fee book-to-bill exceeded 1.3x in each of the past two reported quarters, with management expecting it to remain above 1.2x in Q2. This suggests the company should resume attractive growth next year. Importantly, ICLR's bookings growth outpaced its large clinical research organization (CRO) peers, providing evidence that its competitive position and customer relationships remain intact. As the uncertainty receded and investors refocused on the company's underlying earnings power, the shares rerated. By quickly adding to our ICLR position amidst peak pessimism in mid-February, we were rewarded when its shares appreciated by over 90% in less than five months.” | NEUTRAL | Q2 2026 Jul 29, 2026 | View Pitch |
Harris Associates Concentrated Strategy Tony Coniaris | “ICON was a contributor during the quarter. The Ireland-headquartered and U.S.-listed clinical research organization reported two sets of results as it caught up following its accounting review, both in line with expectations against an improving pharma backdrop. Bookings were the standout, with a strong net book-to-bill and sharply lower cancellations than a year ago, led by full-service outsourcing. Given the business's long-cycle nature, this should support accelerating revenue growth in coming years if sustained. Margins met guidance, and management is confident in further gains from steps already underway. With the accounting clean-up behind it, ICON plans to resume buybacks, its top capital priority, after next quarter's earnings. We continue to see ICON as the leading pure play in an attractive industry with a long runway for future growth.” | BULL | Q2 2026 Jul 28, 2026 | View Pitch |
City Different Investments - Global Equity Vinson Walden | “ICON Plc (ICLR) was a new purchase and became the top contributor to our results for the second quarter. Founded in 1990 by two Irish doctors, this Dublin-based provider of clinical research services and analytics saw its stock price clobbered over the past two years due to the triple whammy of: 1/ a post-COVID-19 demand slowdown; 2/ AI-related fears; and 3/ an accounting error that led to a minor restatement of results. However, our team has followed this industry since 2019, and we bought ICON eagerly in April once the valuation became compelling. Now the accounting error has already been fixed, and leading growth indicators, such as bookings and cancellations, are encouraging. Our research suggests that ICON could be a net beneficiary of AI due to proprietary data, domain expertise, and regulatory barriers, among other factors. A combination of an improving growth rate and a declining share count could boost ICON's valuation from here.” | BULL | Q2 2026 Jul 21, 2026 | View Pitch |
GreensKeeper Value Fund Michael P. McCloskey | “ICON Plc fell sharply after announcing an internal investigation into revenue recognition, which the manager views as a temporary overreaction since the restatement impact is expected to be under 2%. The manager added to the position, confident in the company's $1 billion free cash flow, 10x trailing earnings valuation, and long-term clinical trial prospects.” | BULL | Q1 2026 Apr 26, 2026 | View Pitch |
GreensKeeper Value Fund Michael P. McCloskey | “Since publishing our thesis on ICON PLC, the industry backdrop has improved. Large pharmaceutical companies signed agreements providing clarity on tariffs and pricing, while biotech activity picked up in the second half of the year. Although the company is managing elevated cancellations, gross business wins remain in line with peers. Once cancellations flow through backlog, revenue growth should reaccelerate. BSD Analysis: ICON is clinical research infrastructure, not a discretionary services vendor. Drug development doesn't stop because funding cycles wobble; it just slows and reprioritizes. Scale matters enormously in CROs because global trials, regulatory coordination, and data integrity are hard to replicate. Investors fixate on biotech funding slowdowns and miss pharma's ongoing need to push pipelines forward. Backlog conversion is lumpy, but contract duration provides visibility. Margin pressure is cyclical, not structural. Consolidation favors large, credible operators when sponsors de-risk execution. This is life sciences plumbing that compounds on a longer clock than sentiment.” | BULL | Q4 2025 Jan 23, 2026 | View Pitch |
Orbis International Equity Graeme Forster, Bo Sang | “Similarly, Icon, a top holding that performs drug trials for the pharma and biotech ecosystem, has been tarred with the same brush as the rest of the sector. The shares halved, falling to a low of around 10 times our estimate of normal earnings—a bargain for a good business with secular growth underpinnings. While we do not know the timing of the recovery from the temporary drop in R&D spending that led to short-term negative operating leverage, we are confident that the industry growth trends will resume, driven by the ongoing need for innovative healthcare as the wealthy baby boomer generation enters their twilight years. BSD Analysis: ICON's moat is scale and embeddedness in pharma R&D workflows—once a sponsor trusts a CRO, switching is costly and risky. The business benefits from outsourcing trends, but demand is cyclical with biotech funding and big pharma pipeline confidence. Backlogs look reassuring until cancellations and delays show up. Pricing power exists in complex trials, but competition remains intense and contracts get renegotiated. Execution risk is operational: patient recruitment, site management, and timeline discipline. M&A can add capability but also integration risk, especially when systems and cultures clash. The bull case is normalization of trial activity and steady margin recovery. The bear case is prolonged biotech weakness and utilization pressure. ICON is a quality cyclical—defensive only if you ignore the cycle.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
GreensKeeper Value Fund Michael P. McCloskey | “ICON plc was the second top contributor in Q3, rising +20.3%. The fund initiated the position earlier in 2025 when investor sentiment toward contract research organizations (CROs) weakened due to tariff and pricing concerns. Despite near-term challenges, ICON's strong execution and its role in facilitating large, globally diverse clinical trials continue to drive confidence. Pharmaceutical firms are resuming R&D commitments as clarity emerges on tariffs and drug pricing under the Trump administration. ICLR remains well-positioned to benefit from increasing demand for larger and more complex clinical studies, particularly for GLP-1 therapies. BSD Analysis: ICON continues to deliver one of the cleanest execution stories in the CRO space, with strong backlog conversion, stable pricing, and a deep presence in complex clinical programs. The PRA Health merger is now fully absorbed, and the combined platform is showing real operating leverage. Demand for outsourced trials remains robust as biotech funding normalizes. ICON's scale, therapeutic expertise, and consistent delivery give it a credibility premium. With industry dynamics improving, ICON screens as a high-visibility, high-margin CRO compounder.” | BULL | Q3 2025 Oct 13, 2025 | View Pitch |
ClearBridge Investments Large Cap Value Dmitry Khaykin, Deepon Nag | “Biotech funding challenges and government funding pressure have negatively impacted companies supporting biopharmaceutical development like contract research organization (CRO) ICON. This has pushed out the timing of a CRO growth recovery, even after multiple quarters of spending rationalization among its customers. We exited ICON due to the lowering of our confidence in the timing of CRO business normalization. BSD Analysis: ICON is a top-tier clinical research organization with deep expertise in running complex trials, particularly in oncology and rare diseases where pharma is spending aggressively. As drug pipelines shift toward biologics and precision medicine, sponsors increasingly rely on CROs like ICON to accelerate timelines and manage regulatory complexity. Its scale, global reach, and strong backlog position it to keep taking share from smaller players who can't match operational depth. The PRA Health acquisition continues to deliver margins and cost synergies, giving ICON meaningful operating leverage as volumes rise. While biotech funding cycles can create temporary noise, the long-term trend toward outsourced R&D is firmly intact. ICON's execution has been consistently strong, and its client relationships tend to be sticky once embedded. This remains a high-quality compounder riding one of the most durable growth arcs in healthcare.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
ClearBridge Investments Large Cap Growth Strategy Erica Furfaro, Margaret Vitrano | “Biotech funding challenges and government funding pressure have negatively impacted companies supporting biopharmaceutical development like contract research organization (CRO) ICON. This has pushed out the timing of a CRO growth recovery, even after multiple quarters of spending rationalization among its customers. We exited ICON due to the lowering of our confidence in the timing of CRO business normalization. BSD Analysis: ICON plc (ICON) ICON is the unavoidable CRO consolidator, capitalizing on the multi-year secular trend of pharmaceutical R&D outsourcing that major biopharma companies cannot reverse. The company's massive scale, solidified by its acquisition of PRA Health Sciences, creates a structural competitive advantage that few rivals can match, making it a critical bottleneck supplier to the global drug development pipeline. While near-term growth has been pressured by cautious biotech funding, ICON is insulated by its sticky, high-dollar strategic partnerships with the largest pharmaceutical firms. The continued robust trailing twelve-month book-to-bill ratio over 1.2x proves that industry demand remains structurally intact, with any temporary stock weakness serving as an attractive entry point for a defensive, high-free-cash-flow compounder. ICON offers exposure to the massive biopharma R&D boom without the binary drug-development risk.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
ClearBridge Investments All Cap Growth Evan Bauman, Erica Furfaro, Aram Green, Amanda Leithe, Margaret Vitrano | “Biotech funding challenges and government funding pressure have negatively impacted companies supporting biopharmaceutical development like contract research organization (CRO) ICON. This has pushed out the timing of a CRO growth recovery, even after multiple quarters of spending rationalization among its customers. We exited ICON due to our declining confidence in the timing of CRO business normalization. BSD Analysis: ICON is a high-quality Contract Research Organization (CRO) that has achieved unprecedented scale and efficiency, making it the definitive platform for outsourced drug development. The entire investment thesis is underpinned by the $12 billion acquisition of PRA Health Sciences, which eliminated a key competitor and created a dominant, top-tier CRO with over $8 billion in trailing revenue. This unmatched scale allows ICON to capture a growing share of the massive and complex clinical trial market, maintaining strategic partnerships with the world's largest biopharma companies. Despite near-term revenue pressures from trial delays, the core of its business is protected by a record $24.7 billion backlog and highly visible cash flow. Management is aggressively deploying its cash to amplify per-share growth, completing $750 million in buybacks year-to-date and achieving a substantial 21.2% Adjusted EBITDA margin. The future is secured by its investment in AI-enabled trial solutions (iSubmit, FORWARD+) and decentralized trials, which structurally accelerate drug development and boost profitability.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Canopy Investors Kris Webster, Michael Poulsen, and Jack McManus | “Icon, a top-tier global clinical research organisation (CRO), saw a 25% reduction in consensus 2027 EPS estimates during the year, and a more than 50% decline in its stock price. In our view, its currently depressed valuation reflects one of two market narratives: either investors believe the reduction in R&D spending by pharma companies in recent years is permanent, thereby limiting Icon's future growth potential, or more likely, the market sees no immediate growth catalysts and views the stock as 'dead money' in the near term. With the stock trading at a 10% free cash flow yield, we consider the downside risk limited and are content to be patient. :contentReference[oaicite:3]{index=3} BSD Analysis: Icon's valuation reset embeds pessimistic assumptions on pharma R&D cycles despite its entrenched competitive positioning and long-term outsourcing tailwinds. With CRO peers trading at materially higher EV/EBITDA multiples, mean reversion offers upside as funding conditions normalize. The company generates strong cash conversion, enabling deleveraging and buybacks. Contract wins and biotech funding recovery serve as forward catalysts.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Diamond Hill Mid Cap Anthony Philipp | “Among our bottom Q2 individual contributors were ICON and Post Holdings. ICON's shares declined during the quarter, as contract research organizations (CROs) broadly underperformed amid ongoing uncertainty around the pace and timing of recovery in biotech and pharmaceutical order volumes. Investor sentiment weakened as visibility into normalized growth trajectories remained limited. BSD Analysis: ICON is a pure-play contract research organization running clinical trials for big pharma and biotech globally. As drug development becomes more complex and expensive, outsourcing to large CROs like ICON becomes almost mandatory. The company benefits from multi-year relationships, deep therapeutic expertise, and a global site network that smaller players cannot replicate. Biotech funding cycles can affect near-term demand, but big pharma's development budgets provide a solid base. Scale and data from thousands of trials give ICON an informational edge in designing and running future studies. Margins are healthy, and the business is asset-light with good cash generation. It's one of the cleaner ways to play the long-term growth in R&D without taking direct drug risk.” | BEAR | Q2 2025 Jun 30, 2025 | View Pitch |
LVS Advisory - Growth LVS Advisory LLC | “LVS Advisory divested from Icon Plc after deeper research revealed that its aggressive M&A strategy created project disruptions, high employee turnover, and substantial debt. Concluding that Medpace's model of serving small biotechs was superior to Icon's large pharma focus, the manager sold the stock for a small profit and reallocated the capital to Medpace.” | BEAR | Q1 2025 Apr 2, 2025 | View Pitch |
LVS Advisory - Event Driven LVS Advisory LLC | “LVS purchased Icon Plc expecting strong CRO sector tailwinds and an attractive valuation, but deeper fundamental research revealed critical flaws. The firm's heavy debt load during a high-interest-rate environment and project disruptions stemming from staff turnover and aggressive M&A integration undermined the core thesis. LVS exited the position with a small profit to reallocate capital into its primary CRO choice.” | BEAR | Q1 2025 Apr 2, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
